The consortium RESPONSE is a cooperation between partners from science and industry within the BMBF-Program "Twenty20 -Partnership for Innovation", 2014-2021. RESPONSE gives its partners opportunities to put medical device innovations into practice more efficiently. In order to accelerate innovation processes, joint efforts are being made along the entire translation chain. RESPONSE is focusing on the development of novel concepts of implantable medical devices for cardiovascular, ophthalmologic and ENT application. Platform technology approaches are being used to extend the range of device applications. See also: www.response.uni-rostock.de
Consortium outline
The coordinated research project "RESPONSE -Partnership for Innovation in Implant Technology" (BMBF program Twenty20 -Partnership for Innovation, 2014 -2021) is focusing on the development of novel concepts of implantable medical devices for cardiovascular, ophthalmologic and otorhinolaryngologic application. Major platform technologies of the RESPONSE consortium comprise stent technology, as well as medical device/drug combination product technology. On this basis, a broad range of applications is being pursued, such as absorbable stents and percutaneous heart valves. The joint research efforts of academia and industry in the RESPONSE consortium address the challenges in implant design, biofunctionalization, process development and production. Particular attention is paid to the process of translation of medical device innovations, see Figure 1 , cost analysis, as well as health technology assessment. 
Current and future work
RESPONSE is particularly active in the field of engineering and testing of stent-based combination products, such as absorbable intravascular magnesium scaffolds for cardiovascular application [1] . Percutaneous heart valve technology is being researched regarding dedicated in vitro testing environments [2] and artificial polymer-based leaflet materials as a replacement for current xenogenic tissue-based materials. Novel fabrication technologies are being adapted for the application in implant technology, such as laser machining, additive manufacturing or electrospinning of polymeric nonwoven fabrics. The latter is being explored towards the generation of graft material for stent coverings, or as artificial leaflet material for heart valve prostheses [3] .
Apart from the cardiovascular system, stents are being researched in ophthalmologic (glaucoma drainage) [4, 5] , otorhinolaryngologic (Eustachian tube, treatment of chronic otitis media) [6] , as well as gynecologic (Fallopian tube), see Figure 2 , and gastroenterologic (pancreas) application. The latter being applied in the context of endoscopic pancreatic necrosectomy [7] , see Figure 3 . Quite recently, the approach of so called 'smart implants' has been incorporated into the RESPONSE consortium in order to include sensors, as well as energy supply technologies as another future enabling toolbox for cardiovascular implants (pressure monitoring, leadless pacing) and beyond. Furthermore, versatile numerical tools are being developed for the structural mechanical and fluid dynamical assessment of implants and implant/host interaction [8] . The field of medical device technology as addressed by RESPONSE is of high social relevance. It holds considerable perspectives regarding the future impact on the improvement of patients' lives. Successful completion of all prerequisites for clinical translation is a key objective for RESPONSE. This involves cost analysis and health technology assessment [9] .
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